E3 PreliminaryPreliminaryPEM unclearMechanisticPeer-reviewedMachine draft
Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome.
Cannon, J G, Angel, J B, Abad, L W et al. · Journal of clinical immunology · 1997 · DOI
Quick Summary
This study examined whether people with ME/CFS have abnormal levels of immune signaling molecules (called interleukins) in their blood compared to healthy people. Researchers collected blood samples from women with ME/CFS and matched healthy controls at different points in their menstrual cycles, and tested how their immune cells responded to physical activity. The findings suggest that ME/CFS may involve differences in how the immune system communicates, possibly related to hormonal changes.
Why It Matters
This study provides mechanistic evidence that ME/CFS involves abnormalities in interleukin-1 signaling, a key inflammatory pathway, potentially explaining why patients experience symptoms similar to those caused by cytokine infusion. Understanding these immune differences, particularly how they interact with hormonal cycles, may help explain why ME/CFS disproportionately affects women and why symptoms worsen during certain menstrual phases.
Observed Findings
- Healthy women's immune cells showed menstrual cycle-dependent changes in IL-1β secretion linked to hormone levels, while ME/CFS patients' cells did not exhibit this pattern.
- ME/CFS patients' immune cells secreted twofold higher IL-1Ra during the follicular menstrual phase compared to controls.
- IL-1sRII release was significantly elevated in ME/CFS patients during both menstrual cycle phases compared to controls.
- Only control subjects showed increased IL-1β secretion 48 hours after acute physical stress (during follicular phase).
Inferred Conclusions
- ME/CFS is associated with an abnormality in IL-1β regulation that may involve reduced sensitivity to estradiol and progesterone.
- The elevated IL-1Ra and IL-1sRII secretion in ME/CFS patients suggests chronic, low-level activation of the immune system.
- The loss of normal menstrual cycle variation in immune response in ME/CFS patients indicates possible dysfunction in hormone-immune interactions.
Remaining Questions
- Do these in vitro findings correlate with circulating interleukin levels in patients' blood during daily life?
- Does this immune abnormality precede ME/CFS onset or develop as a consequence of the disease?
- How do these interleukin abnormalities relate to specific symptom patterns and post-exertional malaise in ME/CFS patients?
What This Study Does Not Prove
This study does not prove that interleukin abnormalities cause ME/CFS symptoms—only that the two are associated in this sample. The findings are from laboratory cell cultures (not whole-body responses), so they may not fully reflect immune function during actual physical activity in living patients. The cross-sectional design cannot establish whether these immune changes are a cause, consequence, or simply a marker of the disease.
Tags
Symptom:Post-Exertional MalaisePainFatigue
Biomarker:CytokinesBlood Biomarker
Method Flag:Small SampleExploratory OnlySex-Stratified
Metadata
- DOI
- 10.1023/a:1027314713231
- PMID
- 9168406
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →